Merck (MRK) and Jiangsu Hengrui Pharmaceuticals, a global pharmaceutical company focused on scientific and technological innovation, have ...

Merck&Co., Inc., an American multinational biopharmaceutical company, has entered into an agreement to acquire the rights to the experimental drug HRS-5346, developed by China's Jiangsu Hengrui ...

(RTTNews) - Merck & Co., Inc. (MRK), a healthcare company, on Tuesday announced signing of an exclusive license agreement for HRS-5346 with Jiangsu Hengrui Pharmaceuticals Co., Ltd. HRS-5346 is an ...

Under terms of the deal, Merck will gain global rights to develop, manufacture, and commercialize HRS-5346 for cardiovascular ...

Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region.

Merck will manufacture and commercialize HRS-5346 worldwide.

Merck secures global rights to HRS-5346, an investigational Lp(a) inhibitor, in a deal with Hengrui Pharma worth up to $1.97 billion.

MSD will pay Hengrui Pharma $200m upfront, up to $1.77bn in development, regulatory and commercial milestones, and royalties ...

MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp (a) inhibitor from China's Jiangsu Hengrui ...

US pharma giant Merck & Co and China’s Jiangsu Hengrui Pharmaceuticals have entered into an exclusive license agreement for ...